Volume 68, Issue 2, Pages 207-213 (August 2015) Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate- specific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study  Pär Stattin, Andrew J. Vickers, Daniel D. Sjoberg, Robert Johansson, Torvald Granfors, Mattias Johansson, Kim Pettersson, Peter T. Scardino, Göran Hallmans, Hans Lilja  European Urology  Volume 68, Issue 2, Pages 207-213 (August 2015) DOI: 10.1016/j.eururo.2015.01.009 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Risk of distant metastasis within 15 yr (dashed line) and 20 yr (solid line) by prostate-specific antigen (PSA). The four areas depicted in dark and light orange reflect the four quartiles of the population distribution of PSA levels. (A) Age 60 yr; (B) age 50 yr. PSA=prostate-specific antigen. European Urology 2015 68, 207-213DOI: (10.1016/j.eururo.2015.01.009) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 Risk of distant metastasis among men with elevated prostate-specific antigen (PSA) by four kallikrein (KLK) panel score. (A) Age 60 yr and PSA ≥3 ng/ml (n=2432). Green line: overall risk of distant metastasis; orange line: risk of distant metastasis among men with four KLK panel score ≥7.5% (62% of the men); blue line: risk of distant metastasis among men with four KLK panel score <7.5% (38% of the men). (B) Age 50 yr and PSA ≥2 ng/ml (n=1692). Green line: overall risk of distant metastasis; orange line: risk of distant metastasis among men with four KLK panel score ≥5% (41% of the men); blue line: risk of distant metastasis among men with four KLK panel score <5% (59% of the men). PSA=prostate-specific antigen. European Urology 2015 68, 207-213DOI: (10.1016/j.eururo.2015.01.009) Copyright © 2015 European Association of Urology Terms and Conditions